A number of biosimilar options to treat the common retina diseases are in development globally. Here’s a highlight of 9 with supporting late-stage data.
/PRNewswire/ The "Ranibizumab (Lucentis) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com s offering. This product provides.